What's Going On With Moderna Stock Friday?
What's Going On With Moderna Stock Friday?
Moderna, Inc. (NASDAQ:MRNA) stock is trending on Friday. The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for its RSV vaccine.
Modern,Inc.(納斯達克: MRNA)股票在週五上漲。該公司宣佈,歐洲藥品管理局的人用藥品委員會已經通過了對其RSV疫苗的積極意見。
The Details: The RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RSV infection. As a result, the European Commission will authorize the vaccine.
細節:RSV疫苗mRNA-1345旨在保護60歲及以上的成年人免受RSV感染引起的呼吸道疾病。因此,歐洲委員會將批准該疫苗。
The positive finding is based on data from the Phase 3 clinical trial ConquerRSV. The trial included 37,000 adults, aged 60 or older, and found an efficacy rate of 83.7% with 3.7 months of median follow-up against lower respiratory tract disease caused by RSV. The study also found sustained vaccine efficacy of 63.3% at a median follow up rate of 8.6 months.
該積極結果基於階段3臨床試驗ConquerRSV的數據。試驗涵蓋了37,000名60歲或以上的成年人,並發現在對抗由RSV引起的下呼吸道疾病時,中位隨訪時間爲3.7個月,有效率達到83.7%。該研究還發現,8.6個月的中位隨訪時間保持了63.3%的疫苗有效性。
"mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors," said Stéphane Bancel, CEO of Moderna.
“mRESVIA可以保護老年人免受RSV嚴重後果,獨特的預裝注射器可提高管理的便利性,節省醫療保健專業人員的時間並減少行政錯誤,”Moderna首席執行官Stéphane Bancel說。
The United States Food and Drug Administration approved the vaccine in May 2024 for adults 60 and older.
美國食品和藥品管理局於2024年5月批准該疫苗用於60歲及以上的成年人。
Analyst Changes: Several analysts have issued price target adjustments recently.
分析師改變看法:幾名分析師最近發表了價格目標的調整。
- On Friday, Needham analyst Joseph Stringer reiterated Moderna with a Hold.
- On Thursday, Evercore ISI Group analyst Cory Kasimov maintained Moderna with a In-Line and maintained a $120 price target.
- Also on Thursday, Piper Sandler analyst Edward Tenthoff reiterated Moderna with a Overweight and maintained a $214 price target.
- 週五,Needham分析師Joseph Stringer重申了對Moderna的持有意見。
- 週四,Evercore ISI Group分析師Cory Kasimov維持了對Moderna的內部意見,並維持了120美元的價格目標。
- 同樣是在週四,Piper Sandler分析師Edward Tenthoff重申了對Moderna的超配評級,並維持了214美元的價格目標。
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
FDA拒絕了Rocket Pharmaceuticals的罕見免疫障礙基因治療方案,要求更多的數據,股票下滑。
MRNA Price Action: At the time of writing, Moderna shares are trading 1.96% lower at $118.80 per data from Benzinga Pro.
MRNA價格行情:截至撰寫本文時,根據Benzinga Pro提供的數據,Moderna股票下跌1.96%,報118.80美元。
Image: Lutsenko_Oleksandr on Shutterstock
圖片:Shutterstock的Lutsenko_Oleksandr
譯文內容由第三人軟體翻譯。